View Financial HealthTheraclion 배당 및 자사주 매입배당 기준 점검 0/6Theraclion 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 19Theraclion SA, Annual General Meeting, Jun 18, 2026Theraclion SA, Annual General Meeting, Jun 18, 2026. Location: 240 avenue pierre brossolette, malakoff France공시 • Apr 22Theraclion SA has filed a Follow-on Equity Offering in the amount of €5.992544 million.Theraclion SA has filed a Follow-on Equity Offering in the amount of €5.992544 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 12,484,467 Price\Range: €0.48 Security Features: Attached Warrants Transaction Features: Rights Offering공시 • Jan 30Theraclion SA to Report Fiscal Year 2025 Results on Apr 16, 2026Theraclion SA announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Apr 16, 2026공시 • Dec 10Theraclion Announces Sonovein Fda Submission Following A Strong Year of Regulatory and Clinical AchievementsTheraclion announced that the full dataset from the U.S. Food and Drug Administration pivotal study has been submitted to the FDA on schedule as part of the De Novo clearance process for Sonovein®?. Based on typical FDA review timelines for comparable devices, a decision is anticipated around mid-2026. FDA clearance would authorize U.S. commercialization, giving access to the largest varicose vein treatment market. In 2025, Sonovein®? also achieved key regulatory milestones, including EU MDR certification and compliance with China's GB 9706.1-2020 standard, strengthening its pathway to long-term commercialization in Europe and future market access in China.공시 • Oct 22Theraclion Secures Key Chinese Certification, Advancing Toward Market Access in ChinaTheraclion SA announced that its Sonovein® has successfully passed China’s GB 9706.1-2020 medical electrical equipment safety standard — the national equivalent of the internationally recognized IEC 60601-1 normative framework. This certification confirms that Sonovein® meets the latest Chinese requirements for electrical safety and focused ultrasound emissions for medical devices, validating the robustness of its design and manufacturing processes. It demonstrates Sonovein®’s ability to meet the stringent technical and safety criteria established by the National Medical Products Administration (NMPA), the Chinese regulatory authority. From a regulatory standpoint, compliance with GB 9706.1-2020 is a pivotal milestone in the NMPA approval pathway, ensuring that Sonovein® fulfills one of the core prerequisites for market authorization in China. This achievement marks significant progress toward market authorization and commercialization in China, one of the world’s largest and most dynamic markets for advanced medical technologies. With this certification secured, Sonovein® remains firmly on track to deliver on its international expansion strategy and bring the benefits of its non-invasive ultrasound innovation to a broader patient population.공시 • Sep 16Theraclion Announces Successful U.S. FDA Pivotal Study with 96.8% Occlusion RateTheraclion announced top-line results from its VEINRESET pivotal U.S. clinical trial today. Primary endpoint met: Occlusion rate at 12 months was 96.8%, confirming strong efficacy. Excellent safety profile: No serious or unanticipated adverse events, only one mild adverse event reported throughout the study. Solid secondary endpoints: Reflux abolition rate of 98.5%. 70 patients across four centers were enrolled and treated in New York (U.S.), New Jersey (U.S.), Vienna (Austria), and Prague (C Czech Republic). The VEINRESET study was a single-arm, prospective, multi-center clinical trial to assess the safety and efficacy of Theraclion's Sonovein device in treating primary insufficiency of Great Saphenous Vein (GSV). The study results showed that 96.8% of treated patients achieved complete vein closure at 12 months, with a 95% confidence interval of 88.3% to 99.2%, thereby meeting the primary endpoint. All secondary endpoints demonstrated favorable device efficacy and safety. At 12-month follow-up, 98.5% of patients did not have reflux. Pain observed in all patients, and symptoms were completely resolved in most patients, according to the Venous Clinical Severity Score (rVCSS). None of the patients underwent complementary procedures. Both patients and investigators were satisfied with the device/procedure outcome. Taken together, the study successfully demonstrated that using HIFU generated by Sonovein is safe and effective for the treatment of symptomatic primary GSV insufficiency. Next steps These results will form the basis of Theraclion's planned submission to the U.S. Food and Drug Administration (FDA). Authorization from FDA would enable Theraclion to access the U.S. market, the largest vein treatment market worldwide.공시 • Jul 25Theraclion SA to Report First Half, 2025 Results on Oct 29, 2025Theraclion SA announced that they will report first half, 2025 results on Oct 29, 2025공시 • Feb 12THERACLION Announces Treatment of First Patients with NewONOVEIN®? 'SpeedPulse' Feature Accelerating TreatmentTHERACLION announced that its latest generation SONOVEIN®? 'SpeedPulse' feature is being tried on patients. SONOVEIN™? achieved a new level of maturity in 2024, with Theraclion maintaining its focus on ongoing R&D and innovation. Key progress has recently been made on the development of new functionalities, particularly in Artificial Intelligence, acoustics and 3D robotics, boosting clinical efficacy and treatment speed. These advancements will drive broader adoption in treatment centers, expanding the addressable market and reinforcing Theraclion's mid-term growth potential. SONOVEIN®®? 'SpeedPulse') significantly reduces treatment time. The tested feature called 'SpeedPulse' integrates improved acoustics and therapeutic ultrasound pulsing, aiming at substantially increasing treatment speed. The trial will span over several months.공시 • Jan 07Theraclion SA to Report Fiscal Year 2024 Results on Apr 29, 2025Theraclion SA announced that they will report fiscal year 2024 results at 5:40 PM, Central European Standard Time on Apr 29, 2025공시 • Oct 31Theraclion SA Provides Turnover Guidance for the Year 2025 and 2026Theraclion SA provided turnover guidance for the year 2025 and 2026. For the year, the company is aiming for a turnover of €2.5 million in 2025. For the year, the company is aiming for a turnover of €5 million in 2026.공시 • Jun 25Sonovein FDA Pivotal Study Treatments Completed: Theraclion Reaches Key Milestone on ScheduleTHERACLION announced that treatments in the United States’ FDA (Food & Drug Administration) pivotal study for SONOVEIN® have concluded, in accordance with the scheduled timeline. A key milestone in the FDA approval process for SONOVEIN® A total of 70 patients have been treated with Sonovein in the clinical trial. Four leading centers took part in this study, in the U.S. and in Europe. Results to be released after 12-month follow-up Following the successful completion of a feasibility study in 2022, the FDA pivotal study was initiated on schedule at the end of 2023. With the conclusion of the treatment phase, a 12-month follow-up period is now beginning, and the study results will be available in the summer of 2025. The market approval application will be submitted to the FDA as soon as the study report becomes available in the second half of 2025, and an approval is expected early 2026 but will depend on the regulatory agency review time.공시 • May 15Theraclion SA, Annual General Meeting, Jun 18, 2024Theraclion SA, Annual General Meeting, Jun 18, 2024. Location: le vaillant, 240 avenue pierre brossolette, malakoff France공시 • Oct 25Theraclion Achieves an Important Milestone on the Road to the U.S. Market: First Patients Treated with Sonovein as Part of the Fda- Approved Pivotal StudyTheraclion announced that it launched the first treatments for its FDA-approved pivotal study on the treatment of varicose veins using SONOVEIN in the United States. Theraclion's strategy is to gain access to key markets in the United States and China as early as possible. The first patient treatments are an essential step towards accessing the world's leading varicose vein market. The Food & Drug Administration (FDA) approved this clinical trial a few months ago, following a successful initial feasibility study last year. Renowned doctor Steve Elias, Director of the Center for Vein Disease at a prestigious New Jersey hospital and member of the renowned American Board of Venous and Lymphatic Medicine and American College of Surgeons, is the principal investigator of this trial, which will be conducted at four centers of excellence in the U.S. and Europe. Results will be available after a 12 month follow-up period, in accordance with the FDA-approved protocol.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 TCLI.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: TCLI.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Theraclion 배당 수익률 vs 시장TCLI.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (TCLI.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Medical Equipment)2.2%분석가 예측 (TCLI.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 TCLI.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 TCLI.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 TCLI.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: TCLI.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 12:16종가2026/04/08 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Theraclion SA는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Fanny MeindreCIC Market Solutions (ESN)Fanny MeindreCIC Market Solutions (ESN)Arnaud GuérinPortzamparc BNP Paribas
공시 • May 19Theraclion SA, Annual General Meeting, Jun 18, 2026Theraclion SA, Annual General Meeting, Jun 18, 2026. Location: 240 avenue pierre brossolette, malakoff France
공시 • Apr 22Theraclion SA has filed a Follow-on Equity Offering in the amount of €5.992544 million.Theraclion SA has filed a Follow-on Equity Offering in the amount of €5.992544 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 12,484,467 Price\Range: €0.48 Security Features: Attached Warrants Transaction Features: Rights Offering
공시 • Jan 30Theraclion SA to Report Fiscal Year 2025 Results on Apr 16, 2026Theraclion SA announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Apr 16, 2026
공시 • Dec 10Theraclion Announces Sonovein Fda Submission Following A Strong Year of Regulatory and Clinical AchievementsTheraclion announced that the full dataset from the U.S. Food and Drug Administration pivotal study has been submitted to the FDA on schedule as part of the De Novo clearance process for Sonovein®?. Based on typical FDA review timelines for comparable devices, a decision is anticipated around mid-2026. FDA clearance would authorize U.S. commercialization, giving access to the largest varicose vein treatment market. In 2025, Sonovein®? also achieved key regulatory milestones, including EU MDR certification and compliance with China's GB 9706.1-2020 standard, strengthening its pathway to long-term commercialization in Europe and future market access in China.
공시 • Oct 22Theraclion Secures Key Chinese Certification, Advancing Toward Market Access in ChinaTheraclion SA announced that its Sonovein® has successfully passed China’s GB 9706.1-2020 medical electrical equipment safety standard — the national equivalent of the internationally recognized IEC 60601-1 normative framework. This certification confirms that Sonovein® meets the latest Chinese requirements for electrical safety and focused ultrasound emissions for medical devices, validating the robustness of its design and manufacturing processes. It demonstrates Sonovein®’s ability to meet the stringent technical and safety criteria established by the National Medical Products Administration (NMPA), the Chinese regulatory authority. From a regulatory standpoint, compliance with GB 9706.1-2020 is a pivotal milestone in the NMPA approval pathway, ensuring that Sonovein® fulfills one of the core prerequisites for market authorization in China. This achievement marks significant progress toward market authorization and commercialization in China, one of the world’s largest and most dynamic markets for advanced medical technologies. With this certification secured, Sonovein® remains firmly on track to deliver on its international expansion strategy and bring the benefits of its non-invasive ultrasound innovation to a broader patient population.
공시 • Sep 16Theraclion Announces Successful U.S. FDA Pivotal Study with 96.8% Occlusion RateTheraclion announced top-line results from its VEINRESET pivotal U.S. clinical trial today. Primary endpoint met: Occlusion rate at 12 months was 96.8%, confirming strong efficacy. Excellent safety profile: No serious or unanticipated adverse events, only one mild adverse event reported throughout the study. Solid secondary endpoints: Reflux abolition rate of 98.5%. 70 patients across four centers were enrolled and treated in New York (U.S.), New Jersey (U.S.), Vienna (Austria), and Prague (C Czech Republic). The VEINRESET study was a single-arm, prospective, multi-center clinical trial to assess the safety and efficacy of Theraclion's Sonovein device in treating primary insufficiency of Great Saphenous Vein (GSV). The study results showed that 96.8% of treated patients achieved complete vein closure at 12 months, with a 95% confidence interval of 88.3% to 99.2%, thereby meeting the primary endpoint. All secondary endpoints demonstrated favorable device efficacy and safety. At 12-month follow-up, 98.5% of patients did not have reflux. Pain observed in all patients, and symptoms were completely resolved in most patients, according to the Venous Clinical Severity Score (rVCSS). None of the patients underwent complementary procedures. Both patients and investigators were satisfied with the device/procedure outcome. Taken together, the study successfully demonstrated that using HIFU generated by Sonovein is safe and effective for the treatment of symptomatic primary GSV insufficiency. Next steps These results will form the basis of Theraclion's planned submission to the U.S. Food and Drug Administration (FDA). Authorization from FDA would enable Theraclion to access the U.S. market, the largest vein treatment market worldwide.
공시 • Jul 25Theraclion SA to Report First Half, 2025 Results on Oct 29, 2025Theraclion SA announced that they will report first half, 2025 results on Oct 29, 2025
공시 • Feb 12THERACLION Announces Treatment of First Patients with NewONOVEIN®? 'SpeedPulse' Feature Accelerating TreatmentTHERACLION announced that its latest generation SONOVEIN®? 'SpeedPulse' feature is being tried on patients. SONOVEIN™? achieved a new level of maturity in 2024, with Theraclion maintaining its focus on ongoing R&D and innovation. Key progress has recently been made on the development of new functionalities, particularly in Artificial Intelligence, acoustics and 3D robotics, boosting clinical efficacy and treatment speed. These advancements will drive broader adoption in treatment centers, expanding the addressable market and reinforcing Theraclion's mid-term growth potential. SONOVEIN®®? 'SpeedPulse') significantly reduces treatment time. The tested feature called 'SpeedPulse' integrates improved acoustics and therapeutic ultrasound pulsing, aiming at substantially increasing treatment speed. The trial will span over several months.
공시 • Jan 07Theraclion SA to Report Fiscal Year 2024 Results on Apr 29, 2025Theraclion SA announced that they will report fiscal year 2024 results at 5:40 PM, Central European Standard Time on Apr 29, 2025
공시 • Oct 31Theraclion SA Provides Turnover Guidance for the Year 2025 and 2026Theraclion SA provided turnover guidance for the year 2025 and 2026. For the year, the company is aiming for a turnover of €2.5 million in 2025. For the year, the company is aiming for a turnover of €5 million in 2026.
공시 • Jun 25Sonovein FDA Pivotal Study Treatments Completed: Theraclion Reaches Key Milestone on ScheduleTHERACLION announced that treatments in the United States’ FDA (Food & Drug Administration) pivotal study for SONOVEIN® have concluded, in accordance with the scheduled timeline. A key milestone in the FDA approval process for SONOVEIN® A total of 70 patients have been treated with Sonovein in the clinical trial. Four leading centers took part in this study, in the U.S. and in Europe. Results to be released after 12-month follow-up Following the successful completion of a feasibility study in 2022, the FDA pivotal study was initiated on schedule at the end of 2023. With the conclusion of the treatment phase, a 12-month follow-up period is now beginning, and the study results will be available in the summer of 2025. The market approval application will be submitted to the FDA as soon as the study report becomes available in the second half of 2025, and an approval is expected early 2026 but will depend on the regulatory agency review time.
공시 • May 15Theraclion SA, Annual General Meeting, Jun 18, 2024Theraclion SA, Annual General Meeting, Jun 18, 2024. Location: le vaillant, 240 avenue pierre brossolette, malakoff France
공시 • Oct 25Theraclion Achieves an Important Milestone on the Road to the U.S. Market: First Patients Treated with Sonovein as Part of the Fda- Approved Pivotal StudyTheraclion announced that it launched the first treatments for its FDA-approved pivotal study on the treatment of varicose veins using SONOVEIN in the United States. Theraclion's strategy is to gain access to key markets in the United States and China as early as possible. The first patient treatments are an essential step towards accessing the world's leading varicose vein market. The Food & Drug Administration (FDA) approved this clinical trial a few months ago, following a successful initial feasibility study last year. Renowned doctor Steve Elias, Director of the Center for Vein Disease at a prestigious New Jersey hospital and member of the renowned American Board of Venous and Lymphatic Medicine and American College of Surgeons, is the principal investigator of this trial, which will be conducted at four centers of excellence in the U.S. and Europe. Results will be available after a 12 month follow-up period, in accordance with the FDA-approved protocol.